A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.
JOURNAL OF CLINICAL ONCOLOGY(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2022)